Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group by Maroun, J. et al.
CURRENT ONCOLOGY—VOLUME 13, NUMBER 2
67
PRACTICE GUIDELINE SERIES
ABSTRACT
Carcinoid tumours are relatively rare and, in general,
slow growing. They can be “non-functioning”
tumours, presenting as a tumour mass, or “function-
ing” tumours secondary to the production of several
biopeptides leading to the carcinoid syndrome.
Though these tumours represent 0.25% of an oncol-
ogy practice, a proper understanding of the clinical
course of the disease and of the importance of appro-
priate diagnostic and therapeutic measures is very
important. Proper patient management can lead to
cure, particularly if the tumour can be fully resected,
or to long-term palliation with medical treatment or
cytoreductive surgery, or both, with significant pro-
longation of survival. A good understanding of the
use of somatostatin analogues to achieve effective
symptomatic control and of the importance of ad-
equate follow-up and cardiac monitoring to prevent
or effectively treat cardiac complications can con-
tribute significantly to optimal control of this com-
plex disease, ultimately improving the quality of life
of affected patients. This article, developed by a group
of Canadian experts, provides a framework that will
assist clinicians in taking an optimal approach to
managing their patients with carcinoid tumour.
KEY WORDS
Carcinoid tumour, carcinoid syndrome, guidelines,
clinical management
1. INTRODUCTION
Carcinoid tumours are relatively rare and slow-grow-
ing tumours that originally were thought to be be-
nign. However, they may become aggressive and
resistant to therapy 1. The tumours can secrete sev-
eral biologically active substances, including seroto-
nin (5-hydroxytryptamine), kallikrein, histamine,
prostaglandins, adrenocorticotropic hormone, gastrin,
calcitonin, and growth hormone, among others. The
gastrointestinal tract accounts for about two thirds of
carcinoids. Within the gastrointestinal tract, most
tumours occur in the small intestine (41.8%), rectum
(27.4%), and stomach (8.7%) 2. A delay of several
years frequently occurs before a diagnosis of carci-
noid tumour is made.
In Canada, carcinoid tumours represent less than
0.25% of the oncology patient load. Practice varies
widely across centres, but a few specialized centres with
large loads are emerging (Novartis Pharmaceuticals
Canada. Canadian Carcinoid Survey 2005. Unpublished
data). In view of the rare occurrence of carcinoids, the
experience of physicians and surgeons with the tumour
is limited, suggesting a need for information that can
facilitate diagnosis and management.
Recently, European guidelines were developed by
the Nordic NE Tumour Group and the European Neu-
roendocrine Tumour Society 3–5. The National Com-
prehensive Cancer Network guidelines 6 were published
in the United States, and in the United Kingdom, guide-
lines were published on behalf of the UKNETwork for
Neuroendocrine Tumours 7. However, in Canada, no
consensus or guideline for diagnosing and managing
this condition has been established. The Canadian Na-
tional Carcinoid Expert Group, whose members have
considerable experience in the field, was convened to
study the practices pertaining to carcinoid tumours in
Canada and to develop guidelines to facilitate diagno-
sis and treatment. The group members reached a con-
sensus (see Table I for consensus categories), and the
present guidelines agree in general with those from
Europe and the United States.
2. EPIDEMIOLOGY
Carcinoid tumours have a low incidence rate of 1.9
per 100,000 8. The overall incidence appears to have
increased since the early 1970s, which may at least
partly reflect better diagnosis and awareness. How-
ever, in Ontario, the incidence rose from 2 per mil-
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lion in 1964 to 22 per million in 2002 (W. Kocha.
Personal communication, June 2005), and the specu-
lation is that the advent and increasing use of proton
pump inhibitors is a major contributory factor to that
increased incidence 9.
Distant metastases may be evident at the time of
diagnosis in 12.9% of patients, but better diagnostic
techniques have contributed to improved survival
rates 2,8. Evolution in diagnostic methods—and in
medical and surgical therapies—has led in recent years
to more active care and a more favourable prognosis
for patients 10. A five-decade analysis of 13,715 car-
cinoid tumours showed an overall 5-year survival rate
of 67.2%, with the best survival rates being recorded
for patients with rectal (88.3%), bronchopulmonary
(73.5%), and appendiceal (71.0%) carcinoids 2.
3. FUNCTIONING AND NON-FUNCTIONING
TUMOURS
Neuroendocrine tumours may be benign or malig-
nant, and functioning (that is, exhibiting excessive
hormone production) or non-functioning 6. Carcinoid
tumours are usually slow-growing, and patients with
gastrointestinal carcinoids may be asymptomatic or
may have vague gastrointestinal complaints that are
often diagnosed as irritable bowel syndrome. Non-
functioning tumours are usually found incidentally
during surgery, and their neuroendocrine origin may
be recognized only after histologic examination. Non-
functioning pancreatic tumours can produce symp-
toms of a mass effect. The symptoms of intermittent
intestinal entrapment seen with most midgut tumours
are attributable to mesenteric fibrosis 11.
Functional tumours secrete bioactive mediators,
notably serotonin, resulting in the manifestations of
carcinoid syndrome, which is characterized by flush-
ing, diarrhea, bronchoconstriction, and palpita-
tions 12–15. Excess serotonin appears to be the major
contributor to cardiac damage (endomyocardial fi-
brosis, tricuspid insufficiency, and pulmonary val-
vular disease), and carcinoid-related heart disease can
have fatal consequences.
Numerous neuropeptides have also been found
in excess in patients with carcinoid tumour. In fact,
there is speculation that one or more combinations
of these neuropeptides may be major contributors to
the occurrence of carcinoid—and especially to flush-
ing and other vasoactive manifestations.
The severity of carcinoid syndrome depends on
tumour size and extent of metastases, especially the
presence of liver metastases or others with direct ac-
cess to the systemic (as opposed to the portal) circu-
lation. Metastases are indicative of advanced disease.
4. BIOCHEMICAL MARKERS
Conventional tumour pathology criteria and DNA
cytometry have limited value in assessing the malig-
nancy of a neuroendocrine tumour. Hence, the de-
tection of substances that are more specific for
carcinoid tumours can facilitate a more exact diag-
nosis. Two markers are primarily used to diagnose
and follow carcinoid tumours: 5-hydroxy-indole-
acetic acid (5-HIAA) and chromogranin A (CgA).
4.1 5-HIAA
Serotonin released by carcinoid tumours is metabo-
lized by monoamine oxidases in the liver, lungs, and
brain to 5-HIAA. When measured in a 24-hour urine
sample, 5-HIAA level has a sensitivity of 73% and a
specificity of 100% for diagnosing carcinoid 16. The
normal range for urinary 5-HIAA is 3–15 mg/24 h,
but the figure may vary depending on the labora-
tory. Up to 45 mg/24 h is considered normal by some
laboratories. Levels of 5-HIAA have no clear correla-
tion with symptoms, but they do fluctuate with
symptomatology.
Additionally, 5-HIAA levels reflect the actions of
somatostatin analogues, with a 50% reduction from
pretreatment levels being indicative of a biochemi-
cal response. However, some patients with carcinoid
tumour have symptoms of flushing with low or nor-
mal levels of 5-HIAA 17,18.
4.2 CgA
Chromogranin A is found in the wall of synaptic
vesicles that store serotonin and glucagons. Levels
of CgA tend to correlate with tumour bulk but not
with symptoms. In general, CgA levels are elevated
in 85%–100% of patients with carcinoid tumour, re-
gardless of whether the tumour is functional or non-
functional. The specificity of CgA has been found to
be 98.4%, and the sensitivity, 62.9% 17–19.
In classical midgut neuroendocrine tumours, CgA
levels are elevated to 100–1000 times normal 20,21.
Measurements of CgA can be helpful, particularly if
5-HIAA is negative, but they are not as specific as
measurements of 5-HIAA. Inflammatory conditions and
renal insufficiency can cause elevations of CgA and,
TABLE I Categories of consensus a
Category 1 Uniform consensus based on high-level evidence
that the recommendation is appropriate.
Category 2A Uniform consensus based on lower level
evidence, including clinical experience, that the
recommendation is appropriate.
Category 2B Non-uniform consensus, but no major disagree-
ment, based on lower-level evidence, including
clinical experience, that the recommendation is
appropriate.
Category 3 Major disagreement that the recommendation is
appropriate.
a All recommendations in this statement are category 2A unless
otherwise indicated.CURRENT ONCOLOGY—VOLUME 13, NUMBER 2
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in rare cases, the cause cannot be identified. Type A
gastritis and treatment with proton pump inhibitors
can raise CgA levels. Change over time may be more
useful than a single CgA value, because CgA levels
are independent of symptoms. Practical problems,
such as availability of the test, may hinder its use.
Furthermore, several different methods for determin-
ing CgA are available, and the choice of method may
affect the results. Chromogranin A appears to undergo
a process of fragmentation, and the fragments detected
by particular tests influence the resulting sensitivity.
4.3 Ki67
The Ki67 antigen is a nuclear protein expressed by
proliferating cells; it is absent in resting cells. Ex-
pression can be tested in resected tissue specimens.
Antibodies to Ki67 are a reliable marker of cell
proliferation 22.
Assessment of Ki67 expression or antibody lev-
els can be useful if chemotherapy is a consideration.
High values (>2%) have some prognostic value for
proliferation; patients with low values (<2%) are
unlikely to benefit from chemotherapy 23. Expression
or antibody levels of Ki67 should be tested in all
patients.
4.4 Recommendations
• Levels of 5-HIAA should be measured at baseline
and at 3- to 4-month intervals in the first year. If
the patient is unstable or symptomatic, if evidence
of disease progression is found, or if a change in
therapy is being considered, measurement of the
5-HIAA level should be repeated.
• In the second year, the frequency of 5-HIAA mea-
surements will depend on the patient’s status. If
the patient is stable, measurements at 6-month
intervals may be appropriate. If the patient has
had a complete macroscopic resection, a measure-
ment every year may be adequate.
• Where the test is available, CgA should be mea-
sured every 3 months in the first year. Elevated
CgA in the absence of other altered parameters
generally warrants further investigation.
4.5 Points for Further Discussion
• Centres and techniques for CgA.
5. DIAGNOSTIC IMAGING
Radiographic and nuclear imaging play important
roles in the diagnosis and management of carcinoid
tumours. Coupling a radioisotope to a molecule that
specifically binds to receptors on tumour cells or that
is selectively transported into tumour cells [for ex-
ample, meta-iodobenzylguanidine (MIBG)] can facili-
tate imaging and can also make it possible to deliver
a radiation dose to the tumour without damaging non-
tumour cells. After an injection of a radionuclide such
as 111In-pentetreotide or 123I- or 131I-MIBG, a gamma
camera can visualize neuroendocrine tumours and
their metastases in the body.
Scintigraphy using 111In-pentetreotide is one of
the most important imaging investigations for iden-
tifying and staging carcinoid tumours of the gas-
trointestinal tract. Use of 123I-MIBG can help to identify
chromaffin cell tumours. Helical computed tomog-
raphy (CT), magnetic resonance imaging (MRI), and
ultrasonography are used for determining the precise
location of tumours and for monitoring response to
treatment. Positron emission tomography (PET) scan-
ning may be used for localizing a tumour when other
imaging techniques have failed. Usually, PET is not
useful because of the low metabolic rate of carcinoid
tumours. However, in the future, if neuroendocrine-
specific markers are used, PET may become the most
sensitive technique.
5.1 111In-Pentetreotide Scintigraphy
Somatostatin is a peptide that acts as an inhibitory
factor by binding to somatostatin receptors. Because
somatostatin has a short half-life (1–2 minutes), long-
acting analogues such as octreotide and lanreotide
have been synthesized. An 111In-labelled somatosta-
tin analogue, pentetreotide, which shares the recep-
tor-binding profile of octreotide, concentrates in
neuroendocrine and some non-neuroendocrine
tumours containing somatostatin receptor subtypes 2
and 5, making it suitable for the radio-imaging of
tumours containing those somatostatin receptor sub-
types. It is highly sensitive and specific for carcinoid
tumours and has similar specificity for both function-
ing and non-functioning tumours.
OctreoScan (Mallinckrodt, St. Louis, MO,
U.S.A.) can show early evidence of lesions not re-
vealed by other procedures. The results are particu-
larly helpful if surgery is being considered. Avidity
on OctreoScan indicates a positive response to octre-
otide and is useful in planning treatment 24–27.
All patients should have an OctreoScan as a base-
line, and patients who have undergone curative sur-
gery should have an annual OctreoScan, unless
clinical conditions indicate otherwise. For example,
if a CT scan of the liver shows disease progression, an
earlier OctreoScan may be required to see if the dis-
ease is progressing to other sites.
5.2 MIBG Scintigraphy
Meta-iodobenzylguanidine concentrates in carcinoid
tumours, and occasionally a carcinoid tumour will
take up MIBG and not octreotide. Hence, 123I- or
131I-labelled MIBG, used in place of octreotide, is in-
creasingly recommended as a diagnostic test for car-
cinoid tumours. Imaging quality is superior with70
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123I-MIBG, currently making it the radiopharmaceuti-
cal of choice 28. Scintigraphy using MIBG is useful for
imaging the extent of a tumour and in particular for
distinguishing between primary and metastatic
tumours. Only 80%–90% of carcinoid tumours ex-
press somatostatin receptors, and MIBG can detect
carcinoid tumours that are negative on OctreoScan.
However, OctreoScan is considered to be the supe-
rior diagnostic test. Radiolabelled MIBG testing is use-
ful in identifying patients who can benefit from MIBG
therapy 27,29,30.
5.3 Conventional Imaging
Conventional imaging—such as triphasic CT, MRI, and
ultrasound—may also be helpful. A CT scan can mea-
sure disease that is not visible on an OctreoScan, and
it may be sufficient to evaluate a tumour prior to radio-
frequency ablation. Magnetic resonance imaging is
not routinely employed in carcinoid tumour, but it
can be helpful if CT or ultrasound results are conflict-
ing or unhelpful.
Another new non-invasive technique for detec-
tion of carcinoid tumours in the future may be
PET 27,31,32—if the appropriate tracers become avail-
able in Canada. Conventional PET with fluorodeoxy-
glucose (FDG) detects only less well–differentiated
neuroendocrine tumours and not the common well-
differentiated neuroendocrine tumours.
5.4 Recommendations
• All patients should have an OctreoScan as a
baseline.
• When no uptake is seen on OctreoScan, a scan
with MIBG should be considered if MIBG is being
considered as a part of therapy.
• The radiologist should be made aware of the ob-
jectives of the imaging and the possible treatment
options and associated benefits.
• Patients who have undergone curative treatment
should have an OctreoScan every year, unless
clinical condition indicates otherwise.
• A scan using FDG-PET should be considered only
for moderately- and poorly-differentiated neuro-
endocrine tumours and not for well-differentiated
tumours.
5.5 Points for Further Discussion
• Any differences between 123I- or 131I-labelled
MIBG, and which one to use.
• Centres where MIBG is available.
6. PRINCIPLES OF MANAGEMENT
The main goals of carcinoid tumour management are
symptom control, biochemical control (that is, nor-
malizing the 5-HIAA level), objective tumour control,
and quality-of-life improvement. Different strategies
are used to manage functioning and non-functioning
carcinoid tumours. Somatostatin analogues for symp-
tom control, frequent debulking, and better manage-
ment of cardiac complications have improved survival
rates.
Debulking (cytoreductive surgery) is a mainstay
of therapy. Resection of the tumour can be curative.
In widely metastatic disease, debulking and bypass-
ing procedures can facilitate medical treatment.
Debulking, laser treatment of metastases, radio-fre-
quency ablation and embolization of liver metastases
(either plain or combined with cytotoxic agents), liver
resection, and, more recently, liver transplant (in se-
lected patients) are possible options 3–6.
Somatostatin analogues such as octreotide and
lanreotide have hormone-blocking properties and
can facilitate the surgical procedure, provide symp-
tom control, and reduce the risk of carcinoid crises
and other severe events. They are first-line agents
in the management of carcinoid syndrome. Alter-
natives in management include various combina-
tions of isotope therapy, addition of interferon, and
use of chemotherapy.
Somatostatin analogues control hypersecretion of
neuropeptides in foregut and midgut carcinoid
tumours that express somatostatin receptors, stabi-
lizing the symptoms and possibly contributing to
patient survival. Initially, immediate-release octre-
otide 150 mg is administered subcutaneously three
times daily. Once tolerability and efficacy are estab-
lished (during 3–7 days), 20–30 mg (and up to 60 mg)
of the long-acting formulation (Sandostatin LAR
Depot: Novartis Pharmaceuticals Corporation, East
Hanover, NJ, U.S.A.) is administered intramuscularly
once per month. Immediate-release octreotide may
be used to prevent breakthrough symptoms that may
occur during LAR therapy or with procedures such as
chemoembolization or surgery.
6.1 Cytoreductive Surgery
Because of the slow growth and relatively favourable
prognosis of carcinoid tumour, some clinicians may
avoid surgery. However, the most common cause of
death is advanced metastases, and long-lasting ben-
efit can be obtained by disease ablation. Cyto-
reductive surgery, which aims to control symptoms
and improve survival by removing or destroying the
tumour, is a mainstay in the management of carci-
noid tumour 1,20,23,33. It may include tumour resec-
tion, radio-frequency ablation, and cryotherapy. For
smaller tumours, local excision may be successful,
but for larger tumours (>2 cm) more radical surgery
may be required 34,35. In very select cases, liver trans-
plantation has been performed.
Surgery is the only way to obtain a complete cure.
Surgical resection of the primary tumour in midgut
carcinoids and in cases with lymph node or liverCURRENT ONCOLOGY—VOLUME 13, NUMBER 2
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involvement can improve survival. A delay in resec-
tion of a primary in the bowel, even if metastases
have been identified, will make later attempts at re-
section more difficult. In the presence of metastases,
surgery can improve hormone-related symptoms and
quality of life, and can prolong survival in some
patients. It reduces tumour bulk and prevents further
local or systemic effects 23. Even if resection is not
curative, it can be palliative. A meta-analysis of
cytoreductive partial hepatectomy in patients with
malignant carcinoid tumours showed a 5-year sur-
vival rate of 71% and complete resolution of carci-
noid syndrome symptoms lasting 4–120 months in
86% of cases 36.
Some surgeons might hesitate to undertake such
surgery. This hesitation may be related to difficulty
in resecting the liver or to a lack of understanding of
the value of cytoreduction in this tumour type. It is
therefore worthwhile to identify a surgeon who is
familiar with these procedures and their purpose.
Octreotide administration is crucial before an in-
vasive procedure. In patients whose symptoms are
well controlled with the long-acting form, a supple-
mental dose should be given 1–2 hours before the
procedure. For emergency surgery, octreotide 500–
1000 mg by intravenous bolus or 500 mg subcutane-
ously can be given 1–2 hours before the procedure,
followed by an intravenous infusion 50–200 mg/h. At
the time of surgery, a prophylactic cholecystectomy
should be considered to mitigate the biliary toxicity
of somatostatin analogue therapy 20,37.
6.1.1 Recommendations
• Surgery should be considered, if technically fea-
sible and clinically appropriate, to achieve cure
or maximal debulking and palliation of symptoms.
• All patients should receive cytoreductive surgery
at the earliest opportunity.
• In view of the potential benefits of surgery, re-
luctant surgeons may have to be persuaded to un-
dertake surgery (consensus category 2B), or the
patient may have to be referred to a surgical spe-
cialist who is experienced and knowledgeable
about neuroendocrine tumour surgery.
• Short-acting octreotide should be given before
invasive surgery.
6.2 Liver Metastases
The usual sites for metastases of carcinoid tumour
are liver and bone. Central nervous system involve-
ment is rare, except in the case of thymic carcinoids.
For liver metastases, surgical intervention can be
palliative. Surgical approaches include atypical liver
resection, segmental resection, hemihepatectomy, and
extended hemihepatectomy. The approach must be
individualized for each patient. Surgical resections
may be combined with other ablation techniques,
particularly radio-frequency ablation. Intraoperative
ultrasonography should be used to detect metastases
and to determine their relationship to the hepatic ves-
sels and bile ducts. For multiple liver metastases,
options include debulking surgery, radio-frequency
ablation, cryoablation, laser therapy, radiologic
chemoembolization, medical therapy, or a combina-
tions of these 38–40.
Liver transplantation may be an option for young
patients from whom all extrahepatic tumours and me-
tastases have been removed and in whom no recur-
rence of extrahepatic tumour is expected. However, in
patients who have undergone liver transplantation,
tumours have been found to recur within months or
years 41.
6.2.1 Recommendations
• Surgical treatment by surgeons with expertise
and experience should be considered for liver
metastases.
• The approach must be individualized for each
patient.
6.3 Embolization of Liver Metastases
Because many patients have liver metastases at the
time of diagnosis, treatment aimed at reducing tu-
mour bulk in the liver can prolong survival. Embo-
lization, either alone or in combination with
intra-arterial chemotherapy (chemoembolization), can
reduce clinical symptoms and liver metastases.
An intra-arterial injection of a cytotoxic drug [for
example, 5-fluorouracil (5-FU), doxorubicin, or
mitomycin C] is administered together with non-polar
contrast. The drug concentrations achieved locally
may be 20 times those achieved with systemic intra-
venous injection 3,23,42. Embolization of the supply
artery prevents the contrast–chemotherapy from being
ejected from the tumour vasculature, and it ultimately
interferes with the blood supply to the tumour. A
chemical response is noted in 70%–90% of patients,
and significant tumour reduction in 30% –50% of
patients, with symptomatic response lasting 15–
30 months.
The embolization procedure is associated with a
mortality rate that may be as high as 7% 3. Contra-
indications to liver embolization are complete portal
vein obstruction and hepatic insufficiency, involve-
ment of more than 50% of liver volume, ascites, bil-
iary tract “plumbing,” tumours larger than 7 cm, and
non-permissive vascular supply. Major side effects
include gallbladder necrosis, acute renal failure, pan-
creatitis, and liver abscess.
Details of the procedure, such as the timing of
sequential chemoembolization and choice of cyto-
toxic drugs, are still not clear. More recently, the radio-
contrast agent lipiodol has become available with 131I
instead of cold iodine, permitting embolization with72
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radioactive material. Bland embolization versus
chemoembolization for hepatocellular carcinoma has
been evaluated in three trials, with a significant ad-
vantage for chemoembolization being observed. No
such trials are available for neuroendocrine
carcinoma.
6.3.1 Recommendations
• Where facilities and expertise exist to deliver the
therapy, chemoembolization can be employed to
reduce clinical symptoms and control liver me-
tastases (consensus category 2B).
6.4 Medical Treatment
Systemic treatment for carcinoid tumours includes
therapy with somatostatin analogues, interferon alfa,
and cytotoxic agents. Other agents, such as
loperamide or diphenoxylate for diarrhea and H1 or
H2 blockers (or both) for histamine-secreting tumours
may be administered as required.
6.4.1 Somatostatin Analogues
Somatostatin analogues can relieve symptoms and
reduce hormone levels. They are administered sub-
cutaneously every 6–12 hours. Long-acting formu-
lations require infrequent administration and have
contributed to an improved quality of life for patients.
Somatostatin analogues may be considered for
asymptomatic patients with progressive disease, and
they should be used to prevent or treat carcinoid cri-
ses before, during, and after procedures such as sur-
gery and embolization.
Treatment usually involves the initial subcutane-
ous administration of immediate-release octreotide,
with the long-acting formulation being given after
tolerability and efficacy are established, usually over
3–7 days. Lifelong treatment is likely. Immediate-
release octreotide may also be employed to prevent
breakthrough symptoms occurring with procedures
such as chemoembolization or surgery 1,3,20,23.
Tachyphylaxis and resistance to octreotide are
known to occur. However, it is important to recog-
nize whether an apparent lack of response is being
caused by other factors. For example, patients who
have had a right hemicolectomy or resection of the
terminal ileum but who are not receiving cholestyr-
amine may experience diarrhea. Their diarrhea may
be attributed to carcinoid syndrome when it is ac-
tually due to irritation of the colon by bile acids
that would normally have been absorbed in the ter-
minal ileum. Likewise, diarrhea in patients who
have had multiple bowel resections may be due to
short bowel syndrome, which responds to dietary
modification.
Occasionally, patients who are not tolerating
octreotide may benefit from another somatostatin
analogue, lanreotide. Conversely, patients failing
lanreotide therapy may benefit from octreotide.
Patients not responding to octreotide may also be can-
didates for other therapeutic measures, such as
debulking, hepatic embolization, and radio-frequency
ablation 20.
6.4.2 Interferon Alfa
Interferon alfa inhibits protein and hormone synthe-
sis in tumour cells, inhibits angiogenesis, and stimu-
lates the immune system. It is a primary medical
treatment for low-proliferating gastroenteropancreatic
tumours, either alone or in combination with soma-
tostatin analogues. It may be used as second-line
therapy after cytotoxic treatment, alone or in combi-
nation with somatostatin analogues. The combina-
tion of interferon alfa with somatostatin analogues
has additive and possible synergistic effects in treat-
ing classical carcinoids. Interferon alfa upregulates
the expression of somatostatin receptors, and soma-
tostatin analogues reduce the side effects of interferon
alfa 3,43.
6.4.3 Cytotoxic Treatment
Cytotoxic treatment is usually employed for tumours
with a high proliferative capacity and large tumour
burden (proliferation index by Ki67 antibody > 5%–
10%). Highly proliferating tumours, such as malig-
nant thymic and bronchial carcinoids, derive the
maximum benefit; midgut tumours with low prolif-
eration (Ki67 antibody < 2%) may not benefit from
cytotoxic therapy. Single-agent cytotoxic treatment
produces limited benefit, with response rates of less
than 30%.
The combination of streptozotocin, 5-FU, and
doxorubicin has shown a response rate of more than
50% in malignant pancreatic tumours, but malignant
pulmonary, colorectal, and classical midgut carcinoids
respond poorly to this combination. Poorly differen-
tiated tumours of the foregut (pulmonary, thymic) and
small-cell colorectal tumours have a high prolifera-
tion capacity (Ki67 antibody > 15%), and may re-
spond to cisplatin/paraplatin plus etoposide 3,23.
Poorly differentiated neuroendocrine tumours have
shown a 67% response rate to etoposide plus cisplatin,
but the prognosis is poor, with a 2-year survival of
less than 20% 44–46. Other regimens that have been
used include epirubicin, cisplatin, and fluorouracil;
and imatinib, a new tyrosine-kinase inhibitor; but
results with these regimens are inconclusive.
It needs to be recognized that carcinoid tumours
in particular are often highly desmoplastic, and there-
fore standard endpoints such as tumour response by
mensuration are not valid evaluations of the benefits
of anti-neoplastic therapy. Imaging will visually re-
flect the consequent tumour-induced fibrosis and not
the tumour itself. A more valid approach is therefore
to assess tumour markers, ectopic hormone secretion,
tumour-related symptoms, and organ function of
metastatically-involved viscera.CURRENT ONCOLOGY—VOLUME 13, NUMBER 2
73
PRACTICE GUIDELINE SERIES
6.4.4 Recommendations
• Somatostatin analogues
• are the primary treatment for carcinoid
tumours associated with production of pep-
tides. For patients with insulinoma and
gastrinoma, they may be second- or third-line
agents.
• may be considered for asymptomatic patients
with progressive disease.
• should be used to prevent or treat carcinoid
crises before, during, and after procedures
such as surgery and embolization.
• Standard dosages of somatostatin analogues are
• octreotide: short-acting form, 100–500 mg
three times daily; long-acting form, 10–30 mg
(up to 60 mg) every 4 weeks; and
• lanreotide: slow release form, 60–120 mg
every 4 weeks.
• Interferon alfa (alone or in combination with
somatostatin analogues)
• is a primary medical treatment for low-pro-
liferating gastroenteropancreatic tumours.
• may be a second-line therapy after cytotoxic
treatment.
• should be titrated individually in each patient.
Aim for reduction of leukocyte count to about
3.0×109/L. The usual dosage of regular in-
terferon alfa is 3–5 million units subcutane-
ously, 3 –5 times weekly. The dose of
pegylated interferon alfa is not yet estab-
lished, but may be 75–150 mg subcutaneously
per week.
• Cytotoxic treatment
• may be a first-line treatment for malignant
neuroendocrine tumours in the pancreas and
for gastric carcinoids if Ki67 antibody level
is greater than 10%.
• may be a second-line treatment if other means
of treatment fail, and after tumour-targeted
radioactive treatment.
• agents are used at these dosages: 5-day in-
duction with streptozotocin 1 g daily intra-
venously for 5 days, plus 5-FU 400 mg/m2 on
days 1 3. Thereafter, streptozotocin 2 g and
5-FU 400 mg/m2 intravenously during 1 day
every 3 weeks until toxicity develops. If
doxorubicin is combined with streptozotocin,
40 mg/m2 is given on day 3. One or two years
after stabilization, the interval between
courses may be increased to 4–6 weeks (con-
sensus category 2B).
7. RADIOTHERAPY: EXTERNAL BEAM AND
RADIOISOTOPE THERAPY
External radiation therapy has limited value in carci-
noid tumours; it is recommended only for bone and
brain metastases. Tumour-targeted treatment with
radioactive octreotide derivatives—that is, 111In–
D-Phe(1)-Tyr(3)-octreotide (111In-DOTA-octreotide) or
90Y-DOTA-octreotide and 177Lu-DOTA-octreotate, is
associated with tumour shrinkage in 20%–25% of
tumours and with biochemical and clinical responses
in 40%–50% of patients. In classical midgut
carcinoids, 131I-MIBG can produce biochemical re-
sponses in 30%–40% of patients and tumour re-
sponses in about 20%. However, the exact role of
tumour-targeted radioactive treatment is not yet de-
fined 3. It is nonetheless an accepted alternative in
the therapy of these neoplasms. Some recent evidence
suggests that radioisotope in combination with con-
current chemotherapy may be more efficacious.
8. MONITORING AND FOLLOW-UP
In the first year after diagnosis, patients should be
monitored every 3–4 months to establish the “pace”
of the disease. At each visit, conventional imaging
(triphasic  CT,  MRI, or ultrasonography) should be done,
and urinary 5-HIAA and serum CgA (and possibly
MIBG) should be monitored. If a baseline OctreoScan
is positive, an OctreoScan once yearly is recom-
mended—or earlier if evidence of disease progres-
sion is seen. In the symptomatic patient, the follow-up
schedule will depend on the aggressiveness of the
disease.
In the second and subsequent years, visits every
4–6 months are generally appropriate, with an an-
nual OctreoScan. If surgery, radiation, or a change
in treatment modality is considered, an OctreoScan
or MIBG should be conducted. In the asymptomatic
patient, follow-up involves watchful waiting to en-
sure that no transformation to more aggressive dis-
ease occurs.
Patients who have had a complete macroscopic
resection should have a follow-up every year, with
annual evaluation of 5-HIAA, CgA, and MIBG if avail-
able. If any result is positive, a CT scan and OctreoScan
should be considered.
The use of traditional radiologic methods to as-
sess the response of a neuroendocrine tumour yields
poor results, particularly within the liver. The World
Health Organization and the Response Evaluation
Criteria in Solid Tumours criteria are based largely
on assessment of serial measurements of tumour size
before and after treatment, and are used to define tu-
mour regression.
8.1 Recommendations
• In the first year after diagnosis,
• patients should be monitored every 3–
4 months to establish the “pace” of the disease.
• conventional imaging (triphasic CT, MRI, or
ultrasound), urinary 5-HIAA monitoring, and
serum CgA (and possibly MIBG) should be
done at each visit.74
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• In subsequent years, visits every 4–6 months are
appropriate.
• An annual OctreoScan is recommended unless
more frequent evaluation is indicated. An
OctreoScan may be performed earlier if evidence
of disease progression is seen.
• In the symptomatic patient,
• the follow-up schedule will depend on the
aggressiveness of the disease.
• in the second and subsequent years, follow-
up visits every 4–6 months are appropriate,
with an annual OctreoScan.
• if surgery, radiation, or a change in treatment
modality is considered, an OctreoScan or MIBG
should be conducted.
• In the asymptomatic patient,
• follow-up involves watchful waiting to en-
sure no transformation to more aggressive
disease occurs.
• after complete macroscopic resection, follow-
up should be annual, with an annual evalua-
tion of 5-HIAA, CgA, and MIBG if available.
• if any results are positive, a CT and Octreo-
Scan should be considered.
8.2 Points for Further Discussion
• Should 5-HIAA be controlled with octreotide even
in asymptomatic patients?
• Should the dose of octreotide be increased to
bring 5-HIAA to within normal values?
9. CARCINOID HEART DISEASE
Carcinoid syndrome is associated with the release of
serotonin and other vasoactive substances by the car-
cinoid tumour. Exposure of the heart to high levels
of these substances can result in endocardial dam-
age, manifesting as right-sided endomyocardial fi-
brosis, valvular insufficiency, and heart failure. The
most common lesion is tricuspid regurgitation, fol-
lowed by tricuspid stenosis, pulmonary regurgitation,
and pulmonary stenosis. Right ventricular failure is
a major cause of morbidity and mortality in carci-
noid heart disease 47,48. Cardiac involvement is de-
tected by echocardiography in more than 50% of
patients with carcinoid syndrome 23,49.
Carcinoid heart disease occurs in asymptomatic
patients and in those with small increases in 5-HIAA,
but it is more commonly associated with chronic el-
evation of 5-HIAA. The role of serotonin in the devel-
opment of carcinoid-related heart disease is
controversial, but the indirect evidence appears com-
pelling. Only carcinoid patients with elevated 5-HIAA
levels develop this complication. Serotonin receptors
have been identified in the heart. Experimentally,
stimulation of these receptors causes cardiac cell pro-
liferation. Two drugs, fen-phen and methysergide, can
cause identical cardiac pathology. Both have chemi-
cal structures analogous to serotonin, and both can
be shown to bind to heart serotonin receptors. Re-
cent evidence suggests that both serotonin and atrial
natriuretic factor may be required for the lesions to
occur. Brain natriuretic peptide may be a useful prog-
nostic marker 50.
Carcinoid heart disease is likely to develop in
patients with long-standing elevations of 5-HIAA
(>75 mg/24 h) and is almost never seen in patients
with 5-HIAA values below 50 mg/24 h 51–54. Patients
with 5-HIAA levels greater than 50 mg/24 h should be
considered for octreotide therapy (consensus cate-
gory 2B). Tachyphylaxis with octreotide is more com-
mon in patients with a larger tumour burden.
The symptoms of carcinoid heart disease may be
so subtle as to be attributed to non-cardiac causes.
Hence, it is advisable that patients with carcinoid
syndrome have an echocardiogram at diagnosis.
Patients who are predisposed to carcinoid heart dis-
ease should have an annual echocardiogram and fol-
low-up with a cardiologist.
The use of somatostatin analogues, titrated to
manage symptoms or to normalize 5-HIAA levels, can
help to prevent or minimize carcinoid-related heart
disease, but such use is controversial. Carcinoid heart
disease may continue to progress even if 5-HIAA is
carefully controlled 48.
Once carcinoid heart disease is diagnosed, treat-
ment should be initiated early. Instituting treatment
after the patient has developed pump failure is asso-
ciated with higher mortality. General measures for
heart failure include restricting salt and water intake
and monitoring fluid balance and weight. Right-sided
heart failure is managed with loop diuretics and
digoxin. A thiazide diuretic may be judiciously co-
administered if additional diuresis is required 55.
Cytoreductive surgery to reduce the number of
serotonin receptors can be beneficial 33. Unfortu-
nately, it may be difficult to find a cardiologist who
is interested in treating a patient who has cancer. Some
patients with carcinoid heart disease may benefit from
cardiac valve replacement 56, but cardiac surgeons
may be reluctant to treat these patients. In such cir-
cumstances, the best approach involves close moni-
toring of predisposed patients and aggressive
treatment to prevent heart failure.
9.1 Recommendations
• Patients with carcinoid syndrome should have an
echocardiogram at diagnosis.
• All patients should have an annual echocardio-
gram and follow-up with a cardiologist, particu-
larly those with any cardiac changes or with
elevated 5-HIAA.
• Patients with 5-HIAA levels greater than 50 mg/24 h
should be considered for octreotide therapy (con-
sensus category 2B). Because long-term, low-
level exposure to serotonin may cause cardiacCURRENT ONCOLOGY—VOLUME 13, NUMBER 2
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complications, normalization of 5-HIAA 24-hour
urine excretion is an appropriate goal, if it can be
achieved.
• For carcinoid-related heart disease, the morbid-
ity and mortality rate is so high that early inter-
vention with octreotide should be considered,
given that toxicity is low.
9.2 Point for Discussion
• Patients with 5-HIAA levels greater than 50 mg/
24 h should be considered for octreotide therapy.
10. NEW AGENTS
New agents such as imatinib may be of benefit in
selected patients. Anti-angiogenic substances such as
Endostatin (Entremed, Rockville, MD, U.S.A.),
angiostatin, and the new compound 2004-01-
13IZD6126 may have future roles. A new somatosta-
tin analogue, SOM230, which binds to somatostatin
receptors 1, 2, 3, and 5, could be interesting.
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